About Corrinoid adenosyltransferase MMAB
Corrinoid adenosyltransferase MMAB (MMAB) is a protein
from Homo sapiens identified by UniProt accession
Q96EY8, 250 residues long.
MolForge cross-references it against 0 known binders and
142 disease associations.
Target properties
| Protein name | Corrinoid adenosyltransferase MMAB |
| UniProt accession | Q96EY8 |
| Gene | MMAB |
| Organism | Homo sapiens |
| Length | 250 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (142)
Diseases linked to this target (Open Targets).
- methylmalonic aciduria, cblB type · score 0.81
- Vitamin B12-responsive methylmalonic acidemia type cblB · score 0.80
- methylmalonic acidemia · score 0.55
- genetic disorder · score 0.49
- neurodegenerative disease · score 0.48
- high density lipoprotein cholesterol measurement · score 0.41
- mean platelet volume · score 0.35
- disseminated superficial actinic porokeratosis · score 0.33
- apolipoprotein A 1 measurement · score 0.30
- body mass index · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96EY8-F1 | alphafold | PREDICTED | 81.72 | — |
Amino-acid sequence (250 residues)
MAVCGLGSRL GLGSRLGLRG CFGAARLLYP RFQSRGPQGV EDGDRPQPSS KTPRIPKIYT KTGDKGFSST FTGERRPKDD QVFEAVGTTD ELSSAIGFAL ELVTEKGHTF AEELQKIQCT LQDVGSALAT PCSSAREAHL KYTTFKAGPI LELEQWIDKY TSQLPPLTAF ILPSGGKISS ALHFCRAVCR RAERRVVPLV QMGETDANVA KFLNRLSDYL FTLARYAAMK EGNQEKIYMK NDPSAESEGL
Explore Corrinoid adenosyltransferase MMAB with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets